Reviewer’s report

Title: Medicinal attributes of major phenylpropanoids present in cinnamon

Version: 0 Date: 03 Mar 2016

Reviewer: Mahdi Vazirian

Reviewer's report:

The manuscript entitled "Medicinal attributes of major phenyl-propanoids present in cinnamon" was reviewed and the following comments are offered by the reviewer:

1- Background (Abstract section) must be a part to justify your approach to the subject. I cannot notice the relationship between the sentences. You should explain the relationship between phenylpropanoids and diseases or antioxidant activity.

2- In background section, I cannot understand the radical scavenging and reducing power activity. In which concentration the inhibition has occurred? The same for antibacterial and other effects. It is also a major problem in result section.

3- There are spelling and grammatical errors in the text. For example "Phenylpropanoid" is the correct form of "phenyl-propanoid". I have indicated most of them in PDF file.

4- Being natural is not tantamount to being entirely safe (page 5, line 17).

5- In "Free radical (DPPH) scavenging assay", you have not mention the composition of "control".
6- Can you please explain why you used "two way ANOVA" for statistical analysis?

7- Why you did not measure the IC50 in DPPH method for a better comparison?

8- Eugenol usually is absent in Cinnamon bark essential oil, while it is abundant in cinnamon leaf essential oil. It is better to mention this fact in your text.

9- Which essential oils have eugenol and cinnamaldehyde as their major compound? I do not think that there is a lot (Discussion section).

10- Eugenia caryophyllata is now the synonym of "Syzygium aromaticum (L.) Merr. & L.M.Perry". It is recommended to use the latest accepted scientific names of the plants.

11- You did not mention many other similar works to your study. What is the difference between your work and the others? For example: "DPPH radical-scavenging effect of several phenylpropanoid compounds and their glycoside derivatives." By Timinaga, et al., "Mechanisms of cytotoxicity of eugenol in human osteoblastic cells in vitro." By Ho, et al., "Cytotoxicity and radical intensity of eugenol, isoeugenol or related dimers." Or "Eugenol cytotoxicity evaluated with continuous cell lines." By Babich, et al., Or "Eugenol (an essential oil of clove) acts as an antibacterial agent against Salmonella typhi by disrupting the cellular membrane" by Devi, et al., Or "Antimicrobial activity of eugenol and cinnamaldehyde against extended spectrum beta lactamase producing enterobacteriaceae by in vitro and molecular docking analysis", by Dhara and Tripathi, etc.

12- Table 1 has been repeated in the text.

13- Why you did not use a positive control in antimicrobial test?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

Yes

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal